Combating atherosclerosis with LXR alpha and PPAR alpha agonists: is rational multitargeted polypharmacy the future of therapeutics in complex diseases?
Kino
Tomoshige
T
Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
Chrousos
George P
GP
D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy*; D004268:DNA-Binding Proteins / Q000819:agonists*; D006801:Humans; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D047493:PPAR alpha / Q000819:agonists*; D019338:Polypharmacy; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists*
D004268:DNA-Binding Proteins; D000071518:Liver X Receptors; C000605213:NR1H3 protein, human; D057093:Orphan Nuclear Receptors; D047493:PPAR alpha; D018160:Receptors, Cytoplasmic and Nuclear